The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over
the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy …

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by a reciprocal
translocation [t (9; 22)(q34; q11. 2)] that leads to the fusion of ABL1 gene sequences (9q34) …

Summary Background Tyrosine kinase inhibitors (TKIs) have improved the survival of
patients with chronic myeloid leukaemia. Many patients have deep molecular responses, a …

Purpose Imatinib (IM) can safely be discontinued in patients with chronic myeloid leukemia
(CML) who have had undetectable minimal residual disease (UMRD) for at least 2 years …

The incidence of chronic myeloid leukaemia (CML) ranges between 10 and 15
cases/106/year without any major geographic or ethnic differences [1]. The median age at …

Abstract STOP second generation (2G)–tyrosine kinase inhibitor (TKI) is a multicenter
observational study designed to evaluate 2G-TKI discontinuation in chronic myeloid …

The single-arm, phase 2 ENESTfreedom trial assessed the potential for treatment-free
remission (TFR; ie, the ability to maintain a molecular response after stopping therapy) …

The dramatic success of tyrosine kinase inhibitors (TKIs) has led to the widespread
perception that chronic myeloid leukemia (CML) has become another chronic disease …

The advent of tyrosine kinase inhibitors (TKI) into the management of patients with chronic
myeloid leukemia (CML) has profoundly improved prognosis. Survival of responders is …

Imatinib is effective for the treatment of chronic myeloid leukemia (CML). However even
undetectable BCR‐ABL1 by Q‐RT‐PCR does not equate to eradication of the disease …